お見積

サンプルお申込み

お問い合わせ

今すぐ購入

※ご注文方法：お問い合わせフォームまたはメールにてご連絡ください。
支払方法：「銀行振込」の場合， 注文の確認後、ご指定のメールアドレスに電子版の請求書をお送りいたしますので、電子版の請求書の記載事項に従って送金操作を行ってください。
※納期：原則として、受注後2～4営業日以内に発送いたします。 但し、日本語版が必要な場合は、受注後8～10営業日となります。 お客様のニーズに合わせて、事前にご注文のスケジュールをお立てください。

本報告書は、グルカゴン様ペプチド-1（GLP-1）アゴニストの世界市場、容量、生産量、収益、価格の概要を紹介します。2019~2023年の歴史的な市場収益/売上データ、2024年の予想、および2030年までのCAGRの予測を含む世界市場動向の分析。本レポートはメーカー、地域、製品の種類と端末業界の角度から世界と主要地域の市場現状と将来性を研究した、このレポートでは、世界と主要地域のトップメーカーを分析し、製品タイプとアプリケーション/端末業界別にグルカゴン様ペプチド-1（GLP-1）アゴニスト市場を分類しています。
本レポートでは世界のグルカゴン様ペプチド-1（GLP-1）アゴニスト市場の主な参加者として、企業概要、販売数量、収益、価格、粗利益率、ポートフォリオ、地理的位置、重要な発展を次のパラメータに基づいて紹介します。本研究に含まれる主な企業は：Novo Nordisk、Eli Lilly、AstraZeneca、Sanofi、GSK、Hanson、Shanghai Benemae

レポートはグルカゴン様ペプチド-1（GLP-1）アゴニストの主要生産者を調査し、主要地域や国の消費状況も提供します。グルカゴン様ペプチド-1（GLP-1）アゴニストの今後の市場の可能性のハイライト、およびこの市場をさまざまなセグメントおよびサブセグメントに予測するための主要な地域/国の焦点。アメリカとカナダ、中国、アジア、ヨーロッパ、中東、アフリカ、ラテンアメリカ、およびその他の国の国別データと市場価値分析。

2019年から2030年までのタイプ別および用途別、売上高、収益、価格別のセグメントデータを分析します。
タイプ別市場セグメント：
    Dulaglutide
    Exenatide
    Liraglutide
    Benaglutide
    Other

用途別の市場セグメント：
    Diabetes
    Obesity

本レポートの詳細内容
本レポートは、世界のグルカゴン様ペプチド-1（GLP-1）アゴニスト市場の現状と将来展望を包括的に分析し、グローバルの主要地域における開発動向の綿密な調査を通じて、読者に包括的な市場分析を提示するものであります。市場の全体像を把握するために、プレイヤー、地域、製品タイプ、最終産業を網羅した多角的な分析を提供しています。さらに、世界市場のトッププレイヤーを特定し、プロファイルを作成するとともに、製品タイプや用途/最終産業に基づいてグルカゴン様ペプチド-1（GLP-1）アゴニスト市場を細分化しています。この分類と応用により、市場の構造とダイナミクスをより深く理解することができ、情報に基づいた意思決定と戦略立案が可能になります。
一. 生産面では、2019年から2024年まで、そして2030年までの予測として、メーカー別、地域別（地域レベル、国レベル）のグルカゴン様ペプチド-1（GLP-1）アゴニスト生産量、成長率、市場シェアを調査している。

二. 消費面では、グルカゴン様ペプチド-1（GLP-1）アゴニストの売上高を地域別（地域レベル・国レベル）、企業別、種類別、用途別に焦点を当てています。2019年から2024年まで、2030年までの予測。

三.主要メーカーのグルカゴン様ペプチド-1（GLP-1）アゴニスト売上高、収益、市場シェア、業界ランキング、2019年から2024年までのデータに焦点を当てています。世界のグルカゴン様ペプチド-1（GLP-1）アゴニスト市場における主要なステークホルダーの特定、最近の動向とセグメント収益に基づいて競争状況と市場ポジショニングの分析。

四.本グルカゴン様ペプチド-1（GLP-1）アゴニストのレポートでは関係者が市場の競争状況を包括的に理解し、事業戦略や市場戦略を的確に立てるのに役立つ洞察を提供することを目的としています。 売上高、成長動向、生産技術、用途、エンドユーザー産業の市場規模に関する詳細な評価と予測を提供し、意思決定者に強力なデータサポートを提供します。

章の概要
第1章：グルカゴン様ペプチド-1（GLP-1）アゴニストのレポート範囲、各市場セグメントの市場規模、将来の開発可能性などを含む、さまざまな市場セグメントのエグゼクティブサマリー（タイプ別およびアプリケーション別など）を紹介します。市場の現状と、短期から中期、および長期的な進化の可能性を高度に見ることができます。（2019～2030）
第2章： グルカゴン様ペプチド-1（GLP-1）アゴニストの世界と主要生産者（地域／国）の生産／アウトプット。各生産者の生産量と今後6年間の発展可能性を定量的に分析しています。（2019～2030）
第3章：世界、地域、国レベルにおけるグルカゴン様ペプチド-1（GLP-1）アゴニストの売上（消費）、収益。各地域とその主要国の市場規模と発展の可能性を定量的に分析し、世界の各国の市場発展、将来の発展の見通し、市場空間を紹介します。（2019～2030）
第4章グルカゴン様ペプチド-1（GLP-1）アゴニストメーカーの競争状況、価格、売上高、収益、市場シェアと業界ランキング、最新の開発計画、合併、買収情報などの詳細分析。（2019～2024）
第5章：グルカゴン様ペプチド-1（GLP-1）アゴニストの各市場セグメントの売上高、収益、平均価格、および開発可能性をカバーした種類別のさまざまな市場セグメントの分析を提供し、読者がさまざまな市場セグメントでブルーオーシャン市場を見つけるのに役立ちます。（2019～2030）
第6章：アプリケーション別の様々な市場セグメントの分析を提供し、各市場セグメントの売上高、収益、平均価格、発展の可能性をカバーし、読者が異なる下流市場でのブルーオーシャン市場を見つけるのに役立ちます。（2019～2030）
第7章：北米（米国・カナダ）：タイプ別、用途別、国別、セグメント別の売上高、収益。（2019～2030）
第8章：ヨーロッパ：タイプ別、用途別、国別、セグメント別の売上高と収益。（2019～2030）
第9章：中国：タイプ別、アプリケーション別、セグメント別の売上高、収益。（2019～2030）
第10章：アジア（中国を除く）：タイプ別、用途別、地域別、セグメント別の売上高、収益。（2019～2030）
第11章：中東、アフリカ、中南米：タイプ別、用途別、国別、セグメント別の売上高、収益。（2019～2030）
第12章：グルカゴン様ペプチド-1（GLP-1）アゴニストの主要メーカーの概要を提供し、製品の説明と仕様、グルカゴン様ペプチド-1（GLP-1）アゴニストの売上高、収益、価格、粗利益率、最近の発展など、市場の主要企業の基本的な状況を詳細に紹介します。（2019～2024）
第13章：産業チェーン、販売チャネル、主要原材料、販売代理店および顧客の分析。
第14章：グルカゴン様ペプチド-1（GLP-1）アゴニストの市場動態、市場の最新の動向、市場の推進要因と制約要因、業界内のメーカーが直面する課題とリスク、業界内の関連政策の分析を紹介します。
第15章：レポートの要点と結論。

Glucagon like peptide-1 (GLP-1) agonists is the agonists of the GLP-1 receptor. This class of drugs is used for the treatment of type 2 diabetes. One of their advantages is over older insulin secretagogues, such as sulfonylureas or meglitinides, and they have a lower risk of causing hypoglycemia.
The global Glucagon Like Peptide-1 (GLP-1) Agonists market is projected to grow from US$ 108120 million in 2024 to US$ 401670 million by 2030, at a Compound Annual Growth Rate (CAGR) of 24.5% during the forecast period.
The Glucagon-Like Peptide-1 (GLP-1) Agonists market, which focuses on drugs used for treating type 2 diabetes and obesity, is influenced by several important drivers and challenges:
Market Drivers:
Rising Prevalence of Diabetes and Obesity: The increasing global incidence of type 2 diabetes and obesity is driving demand for GLP-1 agonists, as they are effective in controlling blood sugar levels and aiding weight loss.

Shift Towards Injectable and Oral Therapies: Growing patient acceptance of injectable therapies (such as GLP-1 agonists) and the introduction of oral GLP-1 agonists (like semaglutide) are expanding the market.

Favorable Clinical Outcomes: GLP-1 agonists have shown promising results in managing glycemic control, cardiovascular risk reduction, and weight management, making them a preferred option among healthcare providers.

Increased Awareness and Screening: Governments and healthcare organizations are running campaigns to increase awareness about diabetes management, which is boosting demand for GLP-1 agonists.

Product Innovations: Continuous innovations and the development of longer-acting GLP-1 formulations with fewer side effects are improving patient compliance and market growth.

Market Challenges:
High Treatment Costs: GLP-1 agonists tend to be expensive, which can limit access, particularly in low-income or underdeveloped healthcare systems.

Side Effects and Contraindications: Some patients experience gastrointestinal side effects (like nausea and vomiting) with GLP-1 agonists, potentially limiting widespread use.

Competition from Other Diabetes Treatments: While GLP-1 agonists are effective, there is stiff competition from other diabetes drugs, including DPP-4 inhibitors, SGLT2 inhibitors, and insulin therapies.

Patient Adherence: Although the drug is effective, some patients may struggle with the required injections (for injectable GLP-1 agonists) or discontinuation due to side effects, leading to adherence challenges.

Regulatory and Reimbursement Barriers: The approval process for new GLP-1 agonist formulations, coupled with inconsistent reimbursement policies, can hinder the availability of these drugs in certain markets.

Novo Nordisk, AstraZeneca, Eli Lilly, GSK and Sanofi are the leader of the industry. Novo Nordisk is the top one of this industry. United States is the largest consumer of Glucagon like peptide-1 (GLP-1) agonists The second place is Europe.
Report Includes
This report presents an overview of global market for Glucagon Like Peptide-1 (GLP-1) Agonists, sales, revenue and price. Analyses of the global market trends, with historic market revenue/sales data for 2019 - 2023, estimates for 2024, and projections of CAGR through 2030.
This report researches the key producers of Glucagon Like Peptide-1 (GLP-1) Agonists, also provides the sales of main regions and countries. Highlights of the upcoming market potential for Glucagon Like Peptide-1 (GLP-1) Agonists, and key regions/countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.
This report focuses on the Glucagon Like Peptide-1 (GLP-1) Agonists sales, revenue, market share and industry ranking of main manufacturers, data from 2019 to 2024. Identification of the major stakeholders in the global Glucagon Like Peptide-1 (GLP-1) Agonists market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.
This report analyzes the segments data by Type, and by Application, sales, revenue, and price, from 2019 to 2030. Evaluation and forecast the market size for Glucagon Like Peptide-1 (GLP-1) Agonists sales, projected growth trends, production technology, application and end-user industry.
Descriptive company profiles of the major global players, including Novo Nordisk, Eli Lilly, AstraZeneca, Sanofi, GSK, Hanson, Shanghai Benemae, etc.

Market Segmentation
By Company
    Novo Nordisk
    Eli Lilly
    AstraZeneca
    Sanofi
    GSK
    Hanson
    Shanghai Benemae

Segment by Type
    Dulaglutide
    Exenatide
    Liraglutide
    Benaglutide
    Other

Segment by Application
    Diabetes
    Obesity

Segment by region
    US & Canada
        U.S.
        Canada
    China
    Asia (excluding China)
        Japan
        South Korea
        China Taiwan
        Southeast Asia
        India
        Australia
    Europe
        Germany
        France
        U.K.
        Italy
        Russia

Middle East, Africa, Latin America
        Brazil
        Mexico
        Turkey
        Israel
        GCC Countries

Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, and by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Sales (consumption), revenue of Glucagon Like Peptide-1 (GLP-1) Agonists in global, regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 3: Detailed analysis of Glucagon Like Peptide-1 (GLP-1) Agonists manufacturers competitive landscape, price, sales, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: North America (US & Canada) by Type, by Application and by country, sales, and revenue for each segment.
Chapter 7: Europe by Type, by Application and by country, sales, and revenue for each segment.
Chapter 8: China by Type, and by Application, sales, and revenue for each segment.
Chapter 9: Asia (excluding China) by Type, by Application and by region, sales, and revenue for each segment.
Chapter 10: Middle East, Africa, and Latin America by Type, by Application and by country, sales, and revenue for each segment.
Chapter 11: Provides profiles of key manufacturers, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Glucagon Like Peptide-1 (GLP-1) Agonists sales, revenue, price, gross margin, and recent development, etc.
Chapter 12: Analysis of industrial chain, sales channel, key raw materials, distributors and customers.
Chapter 13: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 14: The main points and conclusions of the report.

List of Tables
 Table 1. Global Glucagon Like Peptide-1 (GLP-1) Agonists Market Size Growth Rate by Type, 2019 VS 2023 VS 2030 (US$ Million)
 Table 2. Major Manufacturers of Dulaglutide
 Table 3. Major Manufacturers of Exenatide
 Table 4. Major Manufacturers of Liraglutide
 Table 5. Major Manufacturers of Benaglutide
 Table 6. Major Manufacturers of Other
 Table 7. Global Glucagon Like Peptide-1 (GLP-1) Agonists Market Size Growth Rate by Application, 2019 VS 2023 VS 2030 (US$ Million)
 Table 8. Global Glucagon Like Peptide-1 (GLP-1) Agonists Revenue Grow Rate (CAGR) by Region: 2019 VS 2023 VS 2030 (US$ Million)
 Table 9. Global Glucagon Like Peptide-1 (GLP-1) Agonists Revenue by Region (2019-2024) & (US$ Million)
 Table 10. Global Glucagon Like Peptide-1 (GLP-1) Agonists Revenue by Region (2025-2030) & (US$ Million)
 Table 11. Global Glucagon Like Peptide-1 (GLP-1) Agonists Revenue Market Share by Region (2019-2024)
 Table 12. Global Glucagon Like Peptide-1 (GLP-1) Agonists Revenue Market Share by Region (2025-2030)
 Table 13. Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales Grow Rate (CAGR) by Region: 2019 VS 2023 VS 2030 (K Units)
 Table 14. Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales by Region (2019-2024) & (K Units)
 Table 15. Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales by Region (2025-2030) & (K Units)
 Table 16. Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales Market Share by Region (2019-2024)
 Table 17. Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales Market Share by Region (2025-2030)
 Table 18. Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales by Manufacturers (2019-2024) & (K Units)
 Table 19. Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales Share by Manufacturers (2019-2024)
 Table 20. Global Glucagon Like Peptide-1 (GLP-1) Agonists Revenue by Manufacturers (2019-2024) & (US$ Million)
 Table 21. Global Glucagon Like Peptide-1 (GLP-1) Agonists Revenue Market Share by Manufacturers (2019-2024)
 Table 22. Global Key Players of Glucagon Like Peptide-1 (GLP-1) Agonists, Industry Ranking, 2021 VS 2022 VS 2023
 Table 23. Glucagon Like Peptide-1 (GLP-1) Agonists Price by Manufacturers (2019-2024) & (USD/Unit)
 Table 24. Global Glucagon Like Peptide-1 (GLP-1) Agonists Manufacturers Market Concentration Ratio (CR5 and HHI)
 Table 25. Global Glucagon Like Peptide-1 (GLP-1) Agonists by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Glucagon Like Peptide-1 (GLP-1) Agonists as of 2023)
 Table 26. Global Key Manufacturers of Glucagon Like Peptide-1 (GLP-1) Agonists, Manufacturing Base Distribution and Headquarters
 Table 27. Global Key Manufacturers of Glucagon Like Peptide-1 (GLP-1) Agonists, Product Offered and Application
 Table 28. Global Key Manufacturers of Glucagon Like Peptide-1 (GLP-1) Agonists, Date of Enter into This Industry
 Table 29. Mergers & Acquisitions, Expansion Plans
 Table 30. Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales by Type (2019-2024) & (K Units)
 Table 31. Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales by Type (2025-2030) & (K Units)
 Table 32. Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales Share by Type (2019-2024)
 Table 33. Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales Share by Type (2025-2030)
 Table 34. Global Glucagon Like Peptide-1 (GLP-1) Agonists Revenue by Type (2019-2024) & (US$ Million)
 Table 35. Global Glucagon Like Peptide-1 (GLP-1) Agonists Revenue by Type (2025-2030) & (US$ Million)
 Table 36. Global Glucagon Like Peptide-1 (GLP-1) Agonists Revenue Share by Type (2019-2024)
 Table 37. Global Glucagon Like Peptide-1 (GLP-1) Agonists Revenue Share by Type (2025-2030)
 Table 38. Glucagon Like Peptide-1 (GLP-1) Agonists Price by Type (2019-2024) & (USD/Unit)
 Table 39. Global Glucagon Like Peptide-1 (GLP-1) Agonists Price Forecast by Type (2025-2030) & (USD/Unit)
 Table 40. Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales by Application (2019-2024) & (K Units)
 Table 41. Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales by Application (2025-2030) & (K Units)
 Table 42. Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales Share by Application (2019-2024)
 Table 43. Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales Share by Application (2025-2030)
 Table 44. Global Glucagon Like Peptide-1 (GLP-1) Agonists Revenue by Application (2019-2024) & (US$ Million)
 Table 45. Global Glucagon Like Peptide-1 (GLP-1) Agonists Revenue by Application (2025-2030) & (US$ Million)
 Table 46. Global Glucagon Like Peptide-1 (GLP-1) Agonists Revenue Share by Application (2019-2024)
 Table 47. Global Glucagon Like Peptide-1 (GLP-1) Agonists Revenue Share by Application (2025-2030)
 Table 48. Glucagon Like Peptide-1 (GLP-1) Agonists Price by Application (2019-2024) & (USD/Unit)
 Table 49. Global Glucagon Like Peptide-1 (GLP-1) Agonists Price Forecast by Application (2025-2030) & (USD/Unit)
 Table 50. US & Canada Glucagon Like Peptide-1 (GLP-1) Agonists Sales by Type (2019-2024) & (K Units)
 Table 51. US & Canada Glucagon Like Peptide-1 (GLP-1) Agonists Sales by Type (2025-2030) & (K Units)
 Table 52. US & Canada Glucagon Like Peptide-1 (GLP-1) Agonists Revenue by Type (2019-2024) & (US$ Million)
 Table 53. US & Canada Glucagon Like Peptide-1 (GLP-1) Agonists Revenue by Type (2025-2030) & (US$ Million)
 Table 54. US & Canada Glucagon Like Peptide-1 (GLP-1) Agonists Sales by Application (2019-2024) & (K Units)
 Table 55. US & Canada Glucagon Like Peptide-1 (GLP-1) Agonists Sales by Application (2025-2030) & (K Units)
 Table 56. US & Canada Glucagon Like Peptide-1 (GLP-1) Agonists Revenue by Application (2019-2024) & (US$ Million)
 Table 57. US & Canada Glucagon Like Peptide-1 (GLP-1) Agonists Revenue by Application (2025-2030) & (US$ Million)
 Table 58. US & Canada Glucagon Like Peptide-1 (GLP-1) Agonists Revenue Grow Rate (CAGR) by Country: 2019 VS 2023 VS 2030 (US$ Million)
 Table 59. US & Canada Glucagon Like Peptide-1 (GLP-1) Agonists Revenue by Country (2019-2024) & (US$ Million)
 Table 60. US & Canada Glucagon Like Peptide-1 (GLP-1) Agonists Revenue by Country (2025-2030) & (US$ Million)
 Table 61. US & Canada Glucagon Like Peptide-1 (GLP-1) Agonists Sales by Country (2019-2024) & (K Units)
 Table 62. US & Canada Glucagon Like Peptide-1 (GLP-1) Agonists Sales by Country (2025-2030) & (K Units)
 Table 63. Europe Glucagon Like Peptide-1 (GLP-1) Agonists Sales by Type (2019-2024) & (K Units)
 Table 64. Europe Glucagon Like Peptide-1 (GLP-1) Agonists Sales by Type (2025-2030) & (K Units)
 Table 65. Europe Glucagon Like Peptide-1 (GLP-1) Agonists Revenue by Type (2019-2024) & (US$ Million)
 Table 66. Europe Glucagon Like Peptide-1 (GLP-1) Agonists Revenue by Type (2025-2030) & (US$ Million)
 Table 67. Europe Glucagon Like Peptide-1 (GLP-1) Agonists Sales by Application (2019-2024) & (K Units)
 Table 68. Europe Glucagon Like Peptide-1 (GLP-1) Agonists Sales by Application (2025-2030) & (K Units)
 Table 69. Europe Glucagon Like Peptide-1 (GLP-1) Agonists Revenue by Application (2019-2024) & (US$ Million)
 Table 70. Europe Glucagon Like Peptide-1 (GLP-1) Agonists Revenue by Application (2025-2030) & (US$ Million)
 Table 71. Europe Glucagon Like Peptide-1 (GLP-1) Agonists Revenue Grow Rate (CAGR) by Country: 2019 VS 2023 VS 2030 (US$ Million)
 Table 72. Europe Glucagon Like Peptide-1 (GLP-1) Agonists Revenue by Country (2019-2024) & (US$ Million)
 Table 73. Europe Glucagon Like Peptide-1 (GLP-1) Agonists Revenue by Country (2025-2030) & (US$ Million)
 Table 74. Europe Glucagon Like Peptide-1 (GLP-1) Agonists Sales by Country (2019-2024) & (K Units)
 Table 75. Europe Glucagon Like Peptide-1 (GLP-1) Agonists Sales by Country (2025-2030) & (K Units)
 Table 76. China Glucagon Like Peptide-1 (GLP-1) Agonists Sales by Type (2019-2024) & (K Units)
 Table 77. China Glucagon Like Peptide-1 (GLP-1) Agonists Sales by Type (2025-2030) & (K Units)
 Table 78. China Glucagon Like Peptide-1 (GLP-1) Agonists Revenue by Type (2019-2024) & (US$ Million)
 Table 79. China Glucagon Like Peptide-1 (GLP-1) Agonists Revenue by Type (2025-2030) & (US$ Million)
 Table 80. China Glucagon Like Peptide-1 (GLP-1) Agonists Sales by Application (2019-2024) & (K Units)
 Table 81. China Glucagon Like Peptide-1 (GLP-1) Agonists Sales by Application (2025-2030) & (K Units)
 Table 82. China Glucagon Like Peptide-1 (GLP-1) Agonists Revenue by Application (2019-2024) & (US$ Million)
 Table 83. China Glucagon Like Peptide-1 (GLP-1) Agonists Revenue by Application (2025-2030) & (US$ Million)
 Table 84. Asia Glucagon Like Peptide-1 (GLP-1) Agonists Sales by Type (2019-2024) & (K Units)
 Table 85. Asia Glucagon Like Peptide-1 (GLP-1) Agonists Sales by Type (2025-2030) & (K Units)
 Table 86. Asia Glucagon Like Peptide-1 (GLP-1) Agonists Revenue by Type (2019-2024) & (US$ Million)
 Table 87. Asia Glucagon Like Peptide-1 (GLP-1) Agonists Revenue by Type (2025-2030) & (US$ Million)
 Table 88. Asia Glucagon Like Peptide-1 (GLP-1) Agonists Sales by Application (2019-2024) & (K Units)
 Table 89. Asia Glucagon Like Peptide-1 (GLP-1) Agonists Sales by Application (2025-2030) & (K Units)
 Table 90. Asia Glucagon Like Peptide-1 (GLP-1) Agonists Revenue by Application (2019-2024) & (US$ Million)
 Table 91. Asia Glucagon Like Peptide-1 (GLP-1) Agonists Revenue by Application (2025-2030) & (US$ Million)
 Table 92. Asia Glucagon Like Peptide-1 (GLP-1) Agonists Revenue Grow Rate (CAGR) by Region: 2019 VS 2023 VS 2030 (US$ Million)
 Table 93. Asia Glucagon Like Peptide-1 (GLP-1) Agonists Revenue by Region (2019-2024) & (US$ Million)
 Table 94. Asia Glucagon Like Peptide-1 (GLP-1) Agonists Revenue by Region (2025-2030) & (US$ Million)
 Table 95. Asia Glucagon Like Peptide-1 (GLP-1) Agonists Sales by Region (2019-2024) & (K Units)
 Table 96. Asia Glucagon Like Peptide-1 (GLP-1) Agonists Sales by Region (2025-2030) & (K Units)
 Table 97. Middle East, Africa and Latin America Glucagon Like Peptide-1 (GLP-1) Agonists Sales by Type (2019-2024) & (K Units)
 Table 98. Middle East, Africa and Latin America Glucagon Like Peptide-1 (GLP-1) Agonists Sales by Type (2025-2030) & (K Units)
 Table 99. Middle East, Africa and Latin America Glucagon Like Peptide-1 (GLP-1) Agonists Revenue by Type (2019-2024) & (US$ Million)
 Table 100. Middle East, Africa and Latin America Glucagon Like Peptide-1 (GLP-1) Agonists Revenue by Type (2025-2030) & (US$ Million)
 Table 101. Middle East, Africa and Latin America Glucagon Like Peptide-1 (GLP-1) Agonists Sales by Application (2019-2024) & (K Units)
 Table 102. Middle East, Africa and Latin America Glucagon Like Peptide-1 (GLP-1) Agonists Sales by Application (2025-2030) & (K Units)
 Table 103. Middle East, Africa and Latin America Glucagon Like Peptide-1 (GLP-1) Agonists Revenue by Application (2019-2024) & (US$ Million)
 Table 104. Middle East, Africa and Latin America Glucagon Like Peptide-1 (GLP-1) Agonists Revenue by Application (2025-2030) & (US$ Million)
 Table 105. Middle East, Africa and Latin America Glucagon Like Peptide-1 (GLP-1) Agonists Revenue Grow Rate (CAGR) by Country: 2019 VS 2023 VS 2030 (US$ Million)
 Table 106. Middle East, Africa and Latin America Glucagon Like Peptide-1 (GLP-1) Agonists Revenue by Country (2019-2024) & (US$ Million)
 Table 107. Middle East, Africa and Latin America Glucagon Like Peptide-1 (GLP-1) Agonists Revenue by Country (2025-2030) & (US$ Million)
 Table 108. Middle East, Africa and Latin America Glucagon Like Peptide-1 (GLP-1) Agonists Sales by Country (2019-2024) & (K Units)
 Table 109. Middle East, Africa and Latin America Glucagon Like Peptide-1 (GLP-1) Agonists Sales by Country (2025-2030) & (K Units)
 Table 110. Novo Nordisk Company Information
 Table 111. Novo Nordisk Description and Major Businesses
 Table 112. Novo Nordisk Glucagon Like Peptide-1 (GLP-1) Agonists Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2019-2024)
 Table 113. Novo Nordisk Glucagon Like Peptide-1 (GLP-1) Agonists Product Model Numbers, Pictures, Descriptions and Specifications
 Table 114. Novo Nordisk Recent Developments
 Table 115. Eli Lilly Company Information
 Table 116. Eli Lilly Description and Major Businesses
 Table 117. Eli Lilly Glucagon Like Peptide-1 (GLP-1) Agonists Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2019-2024)
 Table 118. Eli Lilly Glucagon Like Peptide-1 (GLP-1) Agonists Product Model Numbers, Pictures, Descriptions and Specifications
 Table 119. Eli Lilly Recent Developments
 Table 120. AstraZeneca Company Information
 Table 121. AstraZeneca Description and Major Businesses
 Table 122. AstraZeneca Glucagon Like Peptide-1 (GLP-1) Agonists Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2019-2024)
 Table 123. AstraZeneca Glucagon Like Peptide-1 (GLP-1) Agonists Product Model Numbers, Pictures, Descriptions and Specifications
 Table 124. AstraZeneca Recent Developments
 Table 125. Sanofi Company Information
 Table 126. Sanofi Description and Major Businesses
 Table 127. Sanofi Glucagon Like Peptide-1 (GLP-1) Agonists Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2019-2024)
 Table 128. Sanofi Glucagon Like Peptide-1 (GLP-1) Agonists Product Model Numbers, Pictures, Descriptions and Specifications
 Table 129. Sanofi Recent Developments
 Table 130. GSK Company Information
 Table 131. GSK Description and Major Businesses
 Table 132. GSK Glucagon Like Peptide-1 (GLP-1) Agonists Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2019-2024)
 Table 133. GSK Glucagon Like Peptide-1 (GLP-1) Agonists Product Model Numbers, Pictures, Descriptions and Specifications
 Table 134. GSK Recent Developments
 Table 135. Hanson Company Information
 Table 136. Hanson Description and Major Businesses
 Table 137. Hanson Glucagon Like Peptide-1 (GLP-1) Agonists Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2019-2024)
 Table 138. Hanson Glucagon Like Peptide-1 (GLP-1) Agonists Product Model Numbers, Pictures, Descriptions and Specifications
 Table 139. Hanson Recent Developments
 Table 140. Shanghai Benemae Company Information
 Table 141. Shanghai Benemae Description and Major Businesses
 Table 142. Shanghai Benemae Glucagon Like Peptide-1 (GLP-1) Agonists Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2019-2024)
 Table 143. Shanghai Benemae Glucagon Like Peptide-1 (GLP-1) Agonists Product Model Numbers, Pictures, Descriptions and Specifications
 Table 144. Shanghai Benemae Recent Developments
 Table 145. Key Raw Materials Lists
 Table 146. Raw Materials Key Suppliers Lists
 Table 147. Glucagon Like Peptide-1 (GLP-1) Agonists Distributors List
 Table 148. Glucagon Like Peptide-1 (GLP-1) Agonists Customers List
 Table 149. Glucagon Like Peptide-1 (GLP-1) Agonists Market Trends
 Table 150. Glucagon Like Peptide-1 (GLP-1) Agonists Market Drivers
 Table 151. Glucagon Like Peptide-1 (GLP-1) Agonists Market Challenges
 Table 152. Glucagon Like Peptide-1 (GLP-1) Agonists Market Restraints
 Table 153. Research Programs/Design for This Report
 Table 154. Key Data Information from Secondary Sources
 Table 155. Key Data Information from Primary Sources


List of Figures
 Figure 1. Glucagon Like Peptide-1 (GLP-1) Agonists Product Picture
 Figure 2. Global Glucagon Like Peptide-1 (GLP-1) Agonists Market Size Growth Rate by Type, 2019 VS 2023 VS 2030 (US$ Million)
 Figure 3. Global Glucagon Like Peptide-1 (GLP-1) Agonists Market Share by Type: 2023 & 2030
 Figure 4. Dulaglutide Product Picture
 Figure 5. Exenatide Product Picture
 Figure 6. Liraglutide Product Picture
 Figure 7. Benaglutide Product Picture
 Figure 8. Other Product Picture
 Figure 9. Global Glucagon Like Peptide-1 (GLP-1) Agonists Market Size Growth Rate by Application, 2019 VS 2023 VS 2030 (US$ Million)
 Figure 10. Global Glucagon Like Peptide-1 (GLP-1) Agonists Market Share by Application: 2023 & 2030
 Figure 11. Diabetes
 Figure 12. Obesity
 Figure 13. Glucagon Like Peptide-1 (GLP-1) Agonists Report Years Considered
 Figure 14. Global Glucagon Like Peptide-1 (GLP-1) Agonists Revenue, (US$ Million), 2019 VS 2023 VS 2030
 Figure 15. Global Glucagon Like Peptide-1 (GLP-1) Agonists Revenue (2019-2030) & (US$ Million)
 Figure 16. Global Glucagon Like Peptide-1 (GLP-1) Agonists Revenue (CAGR) by Region: 2019 VS 2023 VS 2030 (US$ Million)
 Figure 17. Global Glucagon Like Peptide-1 (GLP-1) Agonists Revenue Market Share by Region in Percentage: 2023 Versus 2030
 Figure 18. Global Glucagon Like Peptide-1 (GLP-1) Agonists Revenue Market Share by Region (2019-2030)
 Figure 19. Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales (2019-2030) & (K Units)
 Figure 20. Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales (CAGR) by Region: 2019 VS 2023 VS 2030 (K Units)
 Figure 21. Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales Market Share by Region (2019-2030)
 Figure 22. US & Canada Glucagon Like Peptide-1 (GLP-1) Agonists Sales YoY (2019-2030) & (K Units)
 Figure 23. US & Canada Glucagon Like Peptide-1 (GLP-1) Agonists Revenue YoY (2019-2030) & (US$ Million)
 Figure 24. Europe Glucagon Like Peptide-1 (GLP-1) Agonists Sales YoY (2019-2030) & (K Units)
 Figure 25. Europe Glucagon Like Peptide-1 (GLP-1) Agonists Revenue YoY (2019-2030) & (US$ Million)
 Figure 26. China Glucagon Like Peptide-1 (GLP-1) Agonists Sales YoY (2019-2030) & (K Units)
 Figure 27. China Glucagon Like Peptide-1 (GLP-1) Agonists Revenue YoY (2019-2030) & (US$ Million)
 Figure 28. Asia (excluding China) Glucagon Like Peptide-1 (GLP-1) Agonists Sales YoY (2019-2030) & (K Units)
 Figure 29. Asia (excluding China) Glucagon Like Peptide-1 (GLP-1) Agonists Revenue YoY (2019-2030) & (US$ Million)
 Figure 30. Middle East, Africa and Latin America Glucagon Like Peptide-1 (GLP-1) Agonists Sales YoY (2019-2030) & (K Units)
 Figure 31. Middle East, Africa and Latin America Glucagon Like Peptide-1 (GLP-1) Agonists Revenue YoY (2019-2030) & (US$ Million)
 Figure 32. Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales Share by Manufacturers (2023)
 Figure 33. The Glucagon Like Peptide-1 (GLP-1) Agonists Market Share of Top 10 and Top 5 Largest Manufacturers Around the World in 2023
 Figure 34. Global Glucagon Like Peptide-1 (GLP-1) Agonists Revenue Share by Manufacturers (2023)
 Figure 35. The Top 5 and 10 Largest Manufacturers of Glucagon Like Peptide-1 (GLP-1) Agonists in the World: Market Share by Glucagon Like Peptide-1 (GLP-1) Agonists Revenue in 2023
 Figure 36. Global Glucagon Like Peptide-1 (GLP-1) Agonists Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2019 VS 2023
 Figure 37. Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales Market Share by Type (2019-2030)
 Figure 38. Global Glucagon Like Peptide-1 (GLP-1) Agonists Revenue Market Share by Type (2019-2030)
 Figure 39. Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales Market Share by Application (2019-2030)
 Figure 40. Global Glucagon Like Peptide-1 (GLP-1) Agonists Revenue Market Share by Application (2019-2030)
 Figure 41. US & Canada Glucagon Like Peptide-1 (GLP-1) Agonists Sales Market Share by Type (2019-2030)
 Figure 42. US & Canada Glucagon Like Peptide-1 (GLP-1) Agonists Revenue Market Share by Type (2019-2030)
 Figure 43. US & Canada Glucagon Like Peptide-1 (GLP-1) Agonists Sales Market Share by Application (2019-2030)
 Figure 44. US & Canada Glucagon Like Peptide-1 (GLP-1) Agonists Revenue Market Share by Application (2019-2030)
 Figure 45. US & Canada Glucagon Like Peptide-1 (GLP-1) Agonists Revenue Share by Country (2019-2030)
 Figure 46. US & Canada Glucagon Like Peptide-1 (GLP-1) Agonists Sales Share by Country (2019-2030)
 Figure 47. US Glucagon Like Peptide-1 (GLP-1) Agonists Revenue (2019-2030) & (US$ Million)
 Figure 48. Canada Glucagon Like Peptide-1 (GLP-1) Agonists Revenue (2019-2030) & (US$ Million)
 Figure 49. Europe Glucagon Like Peptide-1 (GLP-1) Agonists Sales Market Share by Type (2019-2030)
 Figure 50. Europe Glucagon Like Peptide-1 (GLP-1) Agonists Revenue Market Share by Type (2019-2030)
 Figure 51. Europe Glucagon Like Peptide-1 (GLP-1) Agonists Sales Market Share by Application (2019-2030)
 Figure 52. Europe Glucagon Like Peptide-1 (GLP-1) Agonists Revenue Market Share by Application (2019-2030)
 Figure 53. Europe Glucagon Like Peptide-1 (GLP-1) Agonists Revenue Share by Country (2019-2030)
 Figure 54. Europe Glucagon Like Peptide-1 (GLP-1) Agonists Sales Share by Country (2019-2030)
 Figure 55. Germany Glucagon Like Peptide-1 (GLP-1) Agonists Revenue (2019-2030) & (US$ Million)
 Figure 56. France Glucagon Like Peptide-1 (GLP-1) Agonists Revenue (2019-2030) & (US$ Million)
 Figure 57. U.K. Glucagon Like Peptide-1 (GLP-1) Agonists Revenue (2019-2030) & (US$ Million)
 Figure 58. Italy Glucagon Like Peptide-1 (GLP-1) Agonists Revenue (2019-2030) & (US$ Million)
 Figure 59. Russia Glucagon Like Peptide-1 (GLP-1) Agonists Revenue (2019-2030) & (US$ Million)
 Figure 60. China Glucagon Like Peptide-1 (GLP-1) Agonists Sales Market Share by Type (2019-2030)
 Figure 61. China Glucagon Like Peptide-1 (GLP-1) Agonists Revenue Market Share by Type (2019-2030)
 Figure 62. China Glucagon Like Peptide-1 (GLP-1) Agonists Sales Market Share by Application (2019-2030)
 Figure 63. China Glucagon Like Peptide-1 (GLP-1) Agonists Revenue Market Share by Application (2019-2030)
 Figure 64. Asia Glucagon Like Peptide-1 (GLP-1) Agonists Sales Market Share by Type (2019-2030)
 Figure 65. Asia Glucagon Like Peptide-1 (GLP-1) Agonists Revenue Market Share by Type (2019-2030)
 Figure 66. Asia Glucagon Like Peptide-1 (GLP-1) Agonists Sales Market Share by Application (2019-2030)
 Figure 67. Asia Glucagon Like Peptide-1 (GLP-1) Agonists Revenue Market Share by Application (2019-2030)
 Figure 68. Asia Glucagon Like Peptide-1 (GLP-1) Agonists Revenue Share by Region (2019-2030)
 Figure 69. Asia Glucagon Like Peptide-1 (GLP-1) Agonists Sales Share by Region (2019-2030)
 Figure 70. Japan Glucagon Like Peptide-1 (GLP-1) Agonists Revenue (2019-2030) & (US$ Million)
 Figure 71. South Korea Glucagon Like Peptide-1 (GLP-1) Agonists Revenue (2019-2030) & (US$ Million)
 Figure 72. China Taiwan Glucagon Like Peptide-1 (GLP-1) Agonists Revenue (2019-2030) & (US$ Million)
 Figure 73. Southeast Asia Glucagon Like Peptide-1 (GLP-1) Agonists Revenue (2019-2030) & (US$ Million)
 Figure 74. India Glucagon Like Peptide-1 (GLP-1) Agonists Revenue (2019-2030) & (US$ Million)
 Figure 75. Australia Glucagon Like Peptide-1 (GLP-1) Agonists Revenue (2019-2030) & (US$ Million)
 Figure 76. Middle East, Africa and Latin America Glucagon Like Peptide-1 (GLP-1) Agonists Sales Market Share by Type (2019-2030)
 Figure 77. Middle East, Africa and Latin America Glucagon Like Peptide-1 (GLP-1) Agonists Revenue Market Share by Type (2019-2030)
 Figure 78. Middle East, Africa and Latin America Glucagon Like Peptide-1 (GLP-1) Agonists Sales Market Share by Application (2019-2030)
 Figure 79. Middle East, Africa and Latin America Glucagon Like Peptide-1 (GLP-1) Agonists Revenue Market Share by Application (2019-2030)
 Figure 80. Middle East, Africa and Latin America Glucagon Like Peptide-1 (GLP-1) Agonists Revenue Share by Country (2019-2030)
 Figure 81. Middle East, Africa and Latin America Glucagon Like Peptide-1 (GLP-1) Agonists Sales Share by Country (2019-2030)
 Figure 82. Brazil Glucagon Like Peptide-1 (GLP-1) Agonists Revenue (2019-2030) & (US$ Million)
 Figure 83. Mexico Glucagon Like Peptide-1 (GLP-1) Agonists Revenue (2019-2030) & (US$ Million)
 Figure 84. Turkey Glucagon Like Peptide-1 (GLP-1) Agonists Revenue (2019-2030) & (US$ Million)
 Figure 85. Israel Glucagon Like Peptide-1 (GLP-1) Agonists Revenue (2019-2030) & (US$ Million)
 Figure 86. GCC Countries Glucagon Like Peptide-1 (GLP-1) Agonists Revenue (2019-2030) & (US$ Million)
 Figure 87. Glucagon Like Peptide-1 (GLP-1) Agonists Value Chain
 Figure 88. Glucagon Like Peptide-1 (GLP-1) Agonists Production Process
 Figure 89. Channels of Distribution (Direct Vs Distribution)
 Figure 90. Bottom-up and Top-down Approaches for This Report
 Figure 91. Data Triangulation
 Figure 92. Key Executives Interviewed